This week, we will discuss sparsentan again, but this time in FSGS. This is the largest FSGS trial ever. Will endothelin antagonists crack the sclerotic FSGS segment?
Background
This week, we will discuss the use of renal autologous cell therapy (REACT) in diabetic kidney disease.
Background
This week, we aim for an INFINITe allograft lifespan. or flozination in kidney transplant.
Background
This week, we will discuss the POTCAST trial. It is a cardiology trial - but potassium belongs to nephrology.
